This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): palivizumab, MEDI-493
Description: Synagis (palivizumab) is a humanized monoclonal antibody (IgG1k) produced by recombinant DNAtechnology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is acomposite of human (95%) and murine (5%) antibody sequences.
Deal Structure: Synagis is co-promoted in the U.S. by MedImmune and by the Ross Division of Abbott Laboratories (Abbott). Outside the United States, the International Division of Abbott (AI) has the exclusive right to distribute Synagis. As of January 15, 2003, 50 countries had approved Synagis for marketing: Argentina, Austria, Australia, Bahrain, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Czech Republic, Denmark, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Jordan, Kuwait, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Nicaragua, Norway, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, the United Kingdom, the United States, Uruguay and Venezuela.
Note that Abbott will no longer be involved with the commercialization of this product after the 2005/2006 RSV season.
Synagis was originally developed by MedImmune; in...See full deal structure in Biomedtracker
Partners: Boehringer Ingelheim GmbH Novartis AG AbbVie Inc. PDL BioPharma, Inc. DRI Capital Inc.
Pink Sheet MedImmune Synagis (correction)
Additional information available to subscribers only: